Dr. Charles D. Lopez
Claim this profileOHSU Knight Cancer Institute
Studies Pancreatic Cancer
Studies Gastroesophageal Junction Adenocarcinoma
8 reported clinical trials
19 drugs studied
Area of expertise
1Pancreatic Cancer
Stage IV
Stage III
BRCA1 positive
2Gastroesophageal Junction Adenocarcinoma
Stage IV
Stage III
BRCA1 positive
Affiliated Hospitals
Clinical Trials Charles D. Lopez is currently running
Chemotherapy Switch + Losartan
for Pancreatic Cancer
This phase II trial evaluates whether early switching from modified fluorouracil/irinotecan/leucovorin/oxaliplatin (mFOLFIRINOX) chemotherapy regimen to a combination of gemcitabine and nab-paclitaxel (GA) before surgery is effective in treating patients with pancreatic cancer that can be surgically removed (resectable or borderline resectable), or that has spread to nearby tissue or lymph nodes and cannot be removed by surgery (locally-advanced unresectable). Chemotherapy drugs, such as fluorouracil, irinotecan, leucovorin, oxaliplatin, gemcitabine, and nab-paclitaxel work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The study will also evaluate the drug losartan in combination with mFOLFIRINOX or GA.
Recruiting1 award Phase 220 criteria
Olaparib
for Pancreatic Cancer
This phase II trial investigates how well the addition of olaparib following completion of surgery and chemotherapy works in treating patients with pancreatic cancer that has been surgically removed (resected) and has a pathogenic mutation in BRCA1, BRCA2, or PALB2. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy.
Recruiting0 awards Phase 232 criteria
More about Charles D. Lopez
Clinical Trial Related3 years of experience running clinical trials · Led 8 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Charles D. Lopez has experience with
- Cobimetinib
- Olaparib
- Onvansertib
- Nab-paclitaxel
- Fluorouracil
- Irinotecan Hydrochloride
Breakdown of trials Charles D. Lopez has run
Pancreatic Cancer
Gastroesophageal Junction Adenocarcinoma
Pancreatic Adenocarcinoma
Pancreatic intraepithelial neoplasia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Charles D. Lopez specialize in?
Charles D. Lopez focuses on Pancreatic Cancer and Gastroesophageal Junction Adenocarcinoma. In particular, much of their work with Pancreatic Cancer has involved Stage IV patients, or patients who are Stage III.
Is Charles D. Lopez currently recruiting for clinical trials?
Yes, Charles D. Lopez is currently recruiting for 4 clinical trials in Portland Oregon. If you're interested in participating, you should apply.
Are there any treatments that Charles D. Lopez has studied deeply?
Yes, Charles D. Lopez has studied treatments such as Cobimetinib, Olaparib, Onvansertib.
What is the best way to schedule an appointment with Charles D. Lopez?
Apply for one of the trials that Charles D. Lopez is conducting.
What is the office address of Charles D. Lopez?
The office of Charles D. Lopez is located at: OHSU Knight Cancer Institute, Portland, Oregon 97239 United States. This is the address for their practice at the OHSU Knight Cancer Institute.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.